News | Prostate Cancer | October 22, 2018

Trial shows that addition of pelvic lymph node of lymph node treatment and short-term hormone therapy effective at controlling prostate cancer that recurs after prostatectomy

Combined Therapy Including Pelvic Lymph Node Radiation Provides Significant Benefit for Prostate Cancer Patients - late breaking study presented at ASTRO 2018.

The first report of a large, international clinical trial shows that, for men who show signs of prostate cancer after surgical removal of their prostates, extending radiation therapy to the pelvic lymph nodes combined with adding short-term hormone therapy to standard treatment can extend the amount of time before their cancer spreads. The findings, presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), were so encouraging —exceeding rigorous threshold criteria — that the results were released by the research team ahead of schedule.

Men with prostate cancer who are initially treated with prostatectomy — surgical removal of the prostate gland — often face signs of recurrence, usually signaled by a rise in the level of prostate specific antigen (PSA) in the blood. Radiation therapy to the region of the prior prostate surgery (surgical bed) is standard but only effective at keeping PSA low longer than five or more years in 60 to 70 percent of patients, said the study’s lead author, Alan Pollack, M.D., Ph.D., Chair of radiation oncology at the University of Miami and deputy director of the Sylvester Comprehensive Cancer Center.

While a rise in PSA after prostatectomy signals that the cancer is still present, it does not indicate where the cancer is located.  The NRG Oncology/RTOG 0534 SPORRT clinical trial is the first randomized trial to show that radiation therapy to treat the pelvic lymph nodes in addition to standard prostate bed results in significant incremental gains for these patients.

“We looked specifically at men with prostate cancer who began to show signs that the cancer was not completely eradicated after prostatectomy,” said Pollack. “Adding hormone therapy and pelvic lymph node treatment substantively increased the proportion of patients who remained free from disease progression, to the point that we could report the data after an early interim analysis. The degree of the effectiveness of the combination is surprising, but makes sense when you consider other more contemporary evidence using newer PET scanning methods showing that pelvic lymph node recurrences are more common than previously appreciated.”

The SPPORT trial enrolled 1,792 men at centers in the U.S., Canada and Israel from 2008 to 2015. Eligible patients had persistently detectable or rising PSA levels and evidence that some cancer cells were left behind after prostatectomy in the prostate bed, pelvic lymph nodes or elsewhere in the body after prostatectomy. The median patient age was 64 years (range 39-84), most patients (87 percent) were Caucasian, and the men had generally favorable performance status aside from rising PSA.

Patients in the SPPORT trial were randomly placed into three treatment groups: prostate bed radiation therapy (PBRT) alone, PBRT plus short-term androgen deprivation (hormone) therapy (STAD), and PBRT plus pelvic lymph node radiotherapy (PLNRT) plus STAD. Hormone therapy consisted of four-to-six months of androgen deprivation to reduce levels of testosterone, a driver of prostate cancer.

The trial was designed to assess freedom from disease progression at five years following treatment. Findings from a scheduled interim analysis when 1,191 patients had been followed for five years triggered the early release of the findings, explained Pollack. “The level of significance reached at this point was considerable, making it unlikely that the results will change substantively with longer follow-up, although outcomes such as the rates of distant metastasis and survival require much more patient follow-up, ” he said. “Releasing the data at this juncture is important for physicians treating patients with a rising PSA following prostatectomy. The strategy of combining prostate bed and pelvic lymph node radiation therapy with short-term hormone therapy should be much more strongly considered in routine clinical practice than it is currently.”

At five years following treatment, freedom-from-progression (FFP) rates in the interim analysis group were 71.7 percent for PBRT alone, 82.7 percent for PBRT+ADT and 89.1 percent for PLNRT+PBRT+ADT. The FFP rate was highest for the arm combining all three treatments (p<0.0001). Freedom from progression was defined as a PSA nadir of +2, clinical failure or death from any cause, and was nearly identical for across study groups.

Rates of cancer spread were also significantly different between treatment arms. In all eligible patients followed for up to eight years, distant metastases were found in 45 patients in the PBRT-only arm, 38 patients in the PBRT+ADT arm and 25 patients in the PLNRT+PBRT+ADT arm. Distant metastasis rates were significantly lower following the three-treatment approach compared to PBRT alone (Hazard Ratio 0.52, 95% CI: 0.32-0.85) and compared to PBRT+ADT (HR 0.64, 95% CI: 0.39-1.06).

“While it’s common practice to treat the lymph nodes in men with higher-risk prostate cancer treated without prostatectomy first), this study is the most convincing level-I evidence to demonstrate a benefit,” noted  Pollack. “To be seeing differences in distant metastasis with relatively short follow-up speaks to the robustness of the impact, suggesting that the results will be sustained with longer follow-up.”

Another key finding of the SPPORT trial is that short term hormone therapy (also called androgen deprivation therapy or ADT) is a key component of the management of patients with signs of recurrence after prostatectomy. SPPORT is only the second trial to look specifically at adding short-term hormone therapy to radiation for men following prostatectomy, added Pollack. “There is a lot of data showing a benefit from adding short-term hormone therapy in men whose prostate hasn’t been removed, though only one other randomized trial — GETUG 16 — has shown significant improvements after prostatectomy. Our study confirms that adding STAD to PBRT following surgery extends the time to progression.”

Rates of severe side effects (grade three or higher using CTCAEv3.0) were low across treatment groups. During treatment, the main additional severe effects from PLNRT were in relation to blood/bone marrow events. For long-term effects, blood/bone marrow events were also slightly higher in the PLNRT arm, but only grade 2+ events (4.1 percent), not grade 3+ (1.1 percent).

Additional analyses of the SPPORT trial will focus on the magnitude of difference between the experimental treatment arms to isolate the impact of pelvic lymph node treatment relative to androgen deprivation therapy. The research team also described preliminary data that for those with a very low PSA on study entry, there was no improvement from PLNRT+PBRT+STAD over PBRT+STAD;  although, this was an unplanned analysis.

“It’s now a question of management, of whether a PSA threshold or other factors can be used to identify a patient group in which pelvic lymph node treatment is not as beneficial,” concluded Pollack. “Moreover, the role of newer PET tracers that identify pelvic lymph node involvement earlier in this decision process remains a key question. We still need more data, but we’ve taken a significant step forward with this study.”

For more information:

Read more about the Late-breaking Radiation Therapy Clinical Trials at ASTRO 2018.


Resources on Prostate Cancer and Radiation Therapy


Abstract LBA5 – Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial

A. Pollack1, T. G. Karrison2, A. G. Balogh3, D. Low4, D. W. Bruner5, J. S. Wefel6, L. G. Gomella7, E. Vigneault8, J. M. Michalski9, S. Angyalfi10, H. Lukka11, S. L. Faria12, G. Rodrigues13, M. C. Beauchemin14, S. A. Seaward15, A. M. Allen16, D. C. Monitto17, W. Seiferheld2, and H. M. Sandler18; 1University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, 2NRG Oncology SDMC, Philadelphia, PA, 3University of Calgary, Calgary, AB, Canada, 4UCLA, Los Angeles, CA, 5Nell Hodgson Woodruff School of Nursing, and Winship Cancer Institute at Emory University, Atlanta, GA, 6University of Texas MD Anderson Cancer Center, Houston, TX, 7Sidney Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA, 8CHU de Québec, University of Laval, Quebec, QC, Canada, 9Washington University School of Medicine, St. Louis, MO, 10Tom Baker Cancer Centre, Calgary, AB, Canada, 11McMaster University, Hamilton, ON, Canada, 12McGill University Health Centre, Montreal, QC, Canada, 13London Health Sciences Center, London, ON, Canada, 14Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada, 15Kaiser Permanente, Vallejo, CA, 16Davidoff Center, Rabin Medical Center, Tel Aviv, Israel, 17Spartanburg Regional Medical Center, Spartanburg, SC, 18Cedars Sinai Medical Center, Los Angeles, CA

Purpose/Objective(s): To determine in a three-arm randomized trial whether there are incremental gains in freedom from progression (FFP) from the addition of 4-6 months of short term androgen deprivation therapy (STADT) using antiandrogen plus an LHRH agonist, without or with pelvic lymph node treatment (PLNRT), to prostate bed salvage radiotherapy (PBRT).

Materials/Methods: Patients were randomized to PBRT alone (Arm 1), PBRT + STAD (Arm 2), and PLNRT + PBRT + STAD (Arm 3). The FFP primary endpoint included PSA nadir+2, clinical failure, or death from any cause, with censoring for secondary salvage therapy initiated prior to these events. The sample size provided 90% statistical power to detect a 10% absolute FFP improvement at 5 yr in Arm 2 compared to Arm 1 and a 10% absolute improvement at 5 yr in Arm 3 compared to Arm 2 at an overall alpha level of 0.025. On the third planned interim analysis for efficacy and futility based on 1191 eligible patents with 5 yr minimum follow-up, the treatment arms were compared in a stepwise approach to determine if the Haybittle-Peto (HP) threshold boundary of p < 0.001 (one sided) was crossed. Futility evaluation tested the alternative hypotheses at p < 0.001. Adverse events were graded using CTCAEv3.0.

Results: There were 1792 patients enrolled from 2008 – 2015. Median follow-up for those living is 5.4 yr. Ineligible patients included 18, 17, and 21 in Arms 1, 2, and 3. The patient and tumor characteristics for the 1736 eligible patients include a median age of 64 yr (range 39-84), black in 13%, baseline Zubrod status of 0 in 93%, seminal vesicle involvement in 15%, pre-radiotherapy PSA of ≤1.0 ng/ml in 89%, Gleason score < 8 in 83%, and pT2 margin positive or pT3 in 72%. Arms 1, 2, and 3 had 5 yr FFP rates of 71.1%, 82.7% and 89.1%. Arm 3 had the highest rate compared to Arm 1 (p < 0.0001), exceeding the HP boundary. The hazard ratio (HR) between arms 3 and 1 was 0.44 (95% CI: 0.32-0.59). Arm 3 was then compared to Arm 2, yielding a difference of 6.4% (p = 0.0063) and a HR of 0.71 (95% CI: 0.51-0.98). In all eligible patients followed for up to 8 years, there were 45, 38 and 25 patients who developed distant metastasis (DM) in Arms 1, 2 and 3. Without second salvage censoring, the DM hazard ratio for Arm 3 vs Arm 1 was 0.52 (95% CI: 0.32-0.85) and for Arm 3 vs. Arm 2 was 0.64 (95% CI: 0.39-1.06). With IMRT use in 87% of cases, highest late grade 3+ toxicity was observed in 4.3%, 4.9% and 6.0% for renal/genitourinary events and 0.7%, 0.4%, and 1.1% for gastrointestinal events in Arms 1, 2, and 3.

Conclusion: This is the first report of the primary endpoint and is the first randomized trial to show significant incremental improvements in FFP going from PBRT only to PBRT+STAD to PLNRT+PBRT+STAD. The addition of PLNRT resulted in early, meaningful, reductions in failure. Follow-up of patients will further elucidate the magnitude of the differences between arms 2 and 3.

Related Content

News | Proton Therapy

August 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred ...

Time August 05, 2022
News | Radiology Business

August 4, 2022 — The Biden Administration, through the U.S. Department of Health and Human Services and the Centers for ...

Time August 04, 2022
News | Pediatric Imaging

August 3, 2022 — The Jack Martin Fund (JMF) has built on its partnership with the Mount Sinai Health System to provide ...

Time August 03, 2022
Feature | Oncology Information Management Systems (OIMS)

August 2, 2022 — The oncology information systems market is projected to be worth $2.59 Bn by 2022 and is expected to ...

Time August 02, 2022
Feature | Lung Imaging

August 1, 2022 — In recognition of World Lung Cancer Day, the American Lung Association announced new patient resources ...

Time August 01, 2022
News | Nuclear Imaging

July 27, 2022 — Patients for Safer Nuclear Medicine, a coalition of 29 patient advocacy organizations representing ...

Time July 27, 2022
News | Oncology Information Management Systems (OIMS)

July 26, 2022 — The oncology information system market is expected to expand at a 7.8% CAGR. The oncology information ...

Time July 26, 2022
News | Radiation Oncology

July 25, 2022 — RaySearch Laboratories AB announces the launch of RayStation* 12A, the latest version of the company’s ...

Time July 25, 2022
News | ECR

July 25, 2022 — Dunlee unveiled its new oncology bundles for the first time this year, launched at the 2022 European ...

Time July 25, 2022
Feature | Radiology Business

View the July/August digital edition of Imaging Technology News (ITN), including links to videos, comparison charts and ...

Time July 21, 2022
Subscribe Now